Abstract
Purpose: To review treatment outcomes for stereotactic body radiotherapy (SBRT) in medically operable patients with Stage I non-small-cell lung cancer (NSCLC), using a Japanese multi-institutional database. Patients and Methods: Between 1995 and 2004, a total of 87 patients with Stage I NSCLC (median age, 74 years; T1N0M0, n = 65; T2N0M0, n = 22) who were medically operable but refused surgery were treated using SBRT alone in 14 institutions. Stereotactic three-dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. Total dose was 45-72.5 Gy at the isocenter, administered in 3-10 fractions. Median calculated biological effective dose was 116 Gy (range, 100-141 Gy). Data were collected and analyzed retrospectively. Results: During follow-up (median, 55 months), cumulative local control rates for T1 and T2 tumors at 5 years after SBRT were 92% and 73%, respectively. Pulmonary complications above Grade 2 arose in 1 patient (1.1%). Five-year overall survival rates for Stage IA and IB subgroups were 72% and 62%, respectively. One patient who developed local recurrences safely underwent salvage surgery. Conclusion: Stereotactic body radiotherapy is safe and promising as a radical treatment for operable Stage I NSCLC. The survival rate for SBRT is potentially comparable to that for surgery.
Onishi, Hiroshi;
[1]
Shirato, Hiroki;
[2]
Nagata, Yasushi;
[3]
Hiraoka, Masahiro;
[4]
Fujino, Masaharu;
[2]
School of Medicine, Yamanashi University, Yamanashi (Japan)];
Gomi, Kotaro;
[5]
Karasawa, Katsuyuki;
[6]
Hayakawa, Kazushige;
Niibe, Yuzuru;
[7]
Takai, Yoshihiro;
[8]
Kimura, Tomoki;
[9]
Takeda, Atsuya;
[10]
Ouchi, Atsushi;
[11]
Hareyama, Masato;
[12]
Kokubo, Masaki;
[13]
Kozuka, Takuyo;
[14]
Arimoto, Takuro;
[15]
Hara, Ryusuke;
[16]
Itami, Jun;
[17]
Araki, Tsutomu
[1]
- School of Medicine, Yamanashi University, Yamanashi (Japan)
- School of Medicine, Hokkaido University, Sapporo (Japan)
- School of Medicine, Hiroshima University, Hiroshima (Japan)
- School of Medicine, Kyoto University, Kyoto (Japan)
- Cancer Institute Suwa Red-Cross Hospital, Suwa (Japan)
- Tokyo Metropolitan Komagome Hospital, Tokyo (Japan)
- Kitasato University, Kanagawa (Japan)
- School of Medicine, Hirosaki University, Hirosaki (Japan)
- School of Medicine, Kagawa University, Hiroshima (Japan)
- Ofuna Chuo Hospital, Kanagawa (Japan)
- Keijinkai Hospital, Sapporo (Japan)
- Sapporo Medical University, Sapporo (Japan)
- Institute of Biomedical Research and Innovation, Kobe (Japan)
- School of Cancer Institute Ariake Hospital, Tokyo (Japan)
- Kitami Red Cross Hospital, Kitami (Japan)
- National Institute of Radiological Science, Chiba (Japan)
- National Cancer Center, Tokyo (Japan)
Citation Formats
Onishi, Hiroshi, Shirato, Hiroki, Nagata, Yasushi, Hiraoka, Masahiro, Fujino, Masaharu, School of Medicine, Yamanashi University, Yamanashi (Japan)], Gomi, Kotaro, Karasawa, Katsuyuki, Hayakawa, Kazushige, Niibe, Yuzuru, Takai, Yoshihiro, Kimura, Tomoki, Takeda, Atsuya, Ouchi, Atsushi, Hareyama, Masato, Kokubo, Masaki, Kozuka, Takuyo, Arimoto, Takuro, Hara, Ryusuke, Itami, Jun, and Araki, Tsutomu.
Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?.
United States: N. p.,
2011.
Web.
doi:10.1016/J.IJROBP.2009.07.1751.
Onishi, Hiroshi, Shirato, Hiroki, Nagata, Yasushi, Hiraoka, Masahiro, Fujino, Masaharu, School of Medicine, Yamanashi University, Yamanashi (Japan)], Gomi, Kotaro, Karasawa, Katsuyuki, Hayakawa, Kazushige, Niibe, Yuzuru, Takai, Yoshihiro, Kimura, Tomoki, Takeda, Atsuya, Ouchi, Atsushi, Hareyama, Masato, Kokubo, Masaki, Kozuka, Takuyo, Arimoto, Takuro, Hara, Ryusuke, Itami, Jun, & Araki, Tsutomu.
Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?.
United States.
https://doi.org/10.1016/J.IJROBP.2009.07.1751
Onishi, Hiroshi, Shirato, Hiroki, Nagata, Yasushi, Hiraoka, Masahiro, Fujino, Masaharu, School of Medicine, Yamanashi University, Yamanashi (Japan)], Gomi, Kotaro, Karasawa, Katsuyuki, Hayakawa, Kazushige, Niibe, Yuzuru, Takai, Yoshihiro, Kimura, Tomoki, Takeda, Atsuya, Ouchi, Atsushi, Hareyama, Masato, Kokubo, Masaki, Kozuka, Takuyo, Arimoto, Takuro, Hara, Ryusuke, Itami, Jun, and Araki, Tsutomu.
2011.
"Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?"
United States.
https://doi.org/10.1016/J.IJROBP.2009.07.1751.
@misc{etde_22054487,
title = {Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?}
author = {Onishi, Hiroshi, Shirato, Hiroki, Nagata, Yasushi, Hiraoka, Masahiro, Fujino, Masaharu, School of Medicine, Yamanashi University, Yamanashi (Japan)], Gomi, Kotaro, Karasawa, Katsuyuki, Hayakawa, Kazushige, Niibe, Yuzuru, Takai, Yoshihiro, Kimura, Tomoki, Takeda, Atsuya, Ouchi, Atsushi, Hareyama, Masato, Kokubo, Masaki, Kozuka, Takuyo, Arimoto, Takuro, Hara, Ryusuke, Itami, Jun, and Araki, Tsutomu}
abstractNote = {Purpose: To review treatment outcomes for stereotactic body radiotherapy (SBRT) in medically operable patients with Stage I non-small-cell lung cancer (NSCLC), using a Japanese multi-institutional database. Patients and Methods: Between 1995 and 2004, a total of 87 patients with Stage I NSCLC (median age, 74 years; T1N0M0, n = 65; T2N0M0, n = 22) who were medically operable but refused surgery were treated using SBRT alone in 14 institutions. Stereotactic three-dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. Total dose was 45-72.5 Gy at the isocenter, administered in 3-10 fractions. Median calculated biological effective dose was 116 Gy (range, 100-141 Gy). Data were collected and analyzed retrospectively. Results: During follow-up (median, 55 months), cumulative local control rates for T1 and T2 tumors at 5 years after SBRT were 92% and 73%, respectively. Pulmonary complications above Grade 2 arose in 1 patient (1.1%). Five-year overall survival rates for Stage IA and IB subgroups were 72% and 62%, respectively. One patient who developed local recurrences safely underwent salvage surgery. Conclusion: Stereotactic body radiotherapy is safe and promising as a radical treatment for operable Stage I NSCLC. The survival rate for SBRT is potentially comparable to that for surgery.}
doi = {10.1016/J.IJROBP.2009.07.1751}
journal = []
issue = {5}
volume = {81}
journal type = {AC}
place = {United States}
year = {2011}
month = {Dec}
}
title = {Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?}
author = {Onishi, Hiroshi, Shirato, Hiroki, Nagata, Yasushi, Hiraoka, Masahiro, Fujino, Masaharu, School of Medicine, Yamanashi University, Yamanashi (Japan)], Gomi, Kotaro, Karasawa, Katsuyuki, Hayakawa, Kazushige, Niibe, Yuzuru, Takai, Yoshihiro, Kimura, Tomoki, Takeda, Atsuya, Ouchi, Atsushi, Hareyama, Masato, Kokubo, Masaki, Kozuka, Takuyo, Arimoto, Takuro, Hara, Ryusuke, Itami, Jun, and Araki, Tsutomu}
abstractNote = {Purpose: To review treatment outcomes for stereotactic body radiotherapy (SBRT) in medically operable patients with Stage I non-small-cell lung cancer (NSCLC), using a Japanese multi-institutional database. Patients and Methods: Between 1995 and 2004, a total of 87 patients with Stage I NSCLC (median age, 74 years; T1N0M0, n = 65; T2N0M0, n = 22) who were medically operable but refused surgery were treated using SBRT alone in 14 institutions. Stereotactic three-dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. Total dose was 45-72.5 Gy at the isocenter, administered in 3-10 fractions. Median calculated biological effective dose was 116 Gy (range, 100-141 Gy). Data were collected and analyzed retrospectively. Results: During follow-up (median, 55 months), cumulative local control rates for T1 and T2 tumors at 5 years after SBRT were 92% and 73%, respectively. Pulmonary complications above Grade 2 arose in 1 patient (1.1%). Five-year overall survival rates for Stage IA and IB subgroups were 72% and 62%, respectively. One patient who developed local recurrences safely underwent salvage surgery. Conclusion: Stereotactic body radiotherapy is safe and promising as a radical treatment for operable Stage I NSCLC. The survival rate for SBRT is potentially comparable to that for surgery.}
doi = {10.1016/J.IJROBP.2009.07.1751}
journal = []
issue = {5}
volume = {81}
journal type = {AC}
place = {United States}
year = {2011}
month = {Dec}
}